GCP
ABBV icon

Garda Capital Partners’s AbbVie ABBV Stock Holding History

Garda Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,000
Closed -$1.05M – 544
2025
Q1 		$1.05M Buy
+5,000
New +$972K 0.03% 438
2024
Q2 		– Sell
-22,200
Closed -$4.04M – 450
2024
Q1 		$4.04M Buy
+22,200
New +$3.83M 0.17% 157
2023
Q1 		– Sell
-20,000
Closed -$3.23M – 349
2022
Q4 		$3.23M Buy
+20,000
New +$3.07M 0.18% 162

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Garda Capital Partners's ABBV Position: Q1 2023 in Review

Garda Capital Partners sold out of AbbVie (ABBV) in Q1 2023, closing a stake of 3,027 shares — an estimated $489K sold.

Garda Capital Partners first reported a position in ABBV in Q4 2022 and held it in 1 quarter. The position peaked at $489K in Q4 2022. 3,139 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

  • Garda Capital Partners reported no remaining AbbVie position as of Q1 2023 after selling out during the quarter.
  • Garda Capital Partners sold 3,027 AbbVie shares in Q1 2023, an estimated $489K.
  • Garda Capital Partners first reported a position in AbbVie in Q4 2022 and held it in 1 quarter.
  • Garda Capital Partners's AbbVie position peaked at $489K in Q4 2022.
  • 3,139 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on Garda Capital Partners's 13F filing for Q1 2023, filed 10 May 2023.